EAU Edu Platform on GU cancers
Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology
Home
/
KEYNOTE-426 study
Back
KEYNOTE-426 study
2023-06-03
Dr. Rini elaborates on the results of the KEYNOTE-426 study: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced ccRCC.
Share:
Previous
Next
